سعر افودارت 0.5مجم 30 كبسولة 2024

Dutasteride 0.5 mg soft gelatin capsules (Avodart, GlaxoSmithKline; manufactured by Catalent Schorndorf GmbH, Germany), a dual type 1 and type 2 5-alpha-reductase inhibitor used for symptomatic benign prostatic hyperplasia in men; pack of 30 capsules (3 strips of 10).

• Treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.Population: Adult menDailyMed (U.S. National Library of Medicine)
• In combination with the alpha-adrenergic antagonist tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.Population: Adult menDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (1% or more): impotence, decreased libido, ejaculation disorders and breast disorders (e.g. breast enlargement, tenderness).International label, same product · DailyMed (U.S. National Library of Medicine)

• Pregnancy.International label, same product · DailyMed (U.S. National Library of Medicine)
• Clinically significant hypersensitivity (e.g. serious skin reactions, angioedema) to dutasteride, other 5-alpha-reductase inhibitors or any component.International label, same product · DailyMed (U.S. National Library of Medicine)

• Reduces serum PSA by about 50% within 3-6 months, including in the presence of prostate cancer: establish a new PSA baseline after at least 3 months of treatment and, for interpretation of an isolated value, double the PSA; any confirmed PSA increase while on treatment should be evaluated.International label, same product · DailyMed (U.S. National Library of Medicine)
• 5-alpha-reductase inhibitors may increase the risk of high-grade prostate cancer.International label, same product · DailyMed (U.S. National Library of Medicine)
• Before starting, evaluate for other urological diseases, including prostate cancer, that may mimic BPH.International label, same product · DailyMed (U.S. National Library of Medicine)

• Potent, chronic CYP3A4 inhibitors (e.g. ritonavir)Dutasteride is metabolised by CYP3A4/3A5; use caution because exposure may increase (effect not studied).DailyMed (U.S. National Library of Medicine)
• Verapamil, diltiazemDecrease dutasteride clearance and increase exposure; the change is not considered clinically significant and no dose adjustment is recommended.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnancy and not indicated for use in women; as a 5-alpha-reductase inhibitor it may cause abnormal development of the external genitalia of a male fetus. Women who are or may become pregnant should not handle leaking capsules (dutasteride is absorbed through the skin).International label, same product · DailyMed (U.S. National Library of Medicine)
• Not indicated for use in women; there is no information on the presence of dutasteride in human milk or effects on the breastfed child.International label, same product · DailyMed (U.S. National Library of Medicine)

• Dutasteride: Inhibits both type 1 and type 2 isoforms of 5-alpha-reductase, which convert testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for prostate enlargement.